Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure

PHASE3RecruitingINTERVENTIONAL
Enrollment

1,364

Participants

Timeline

Start Date

March 15, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2025

Conditions
Acute Decompensated Heart Failure
Interventions
DRUG

Empagliflozin 10 MG

once daily for 6 or 9 months

DRUG

Dapagliflozin 10 MG

once daily for 6 or 9 months

DRUG

Placebo

once daily for 3 months

Trial Locations (1)

Unknown

RECRUITING

Autonomous Public Specialist Western John Paul II Hospital, Grodzisk Mazowiecki

All Listed Sponsors
collaborator

Medical University of Vienna

OTHER

collaborator

Medical University of Graz

OTHER

collaborator

University Clinical Center of the Medical University of Warsaw

UNKNOWN

collaborator

Jerzy Popiełuszko Bielański Hospital in Warsaw

UNKNOWN

collaborator

Regional Polyclinical Hospital in Kielce

UNKNOWN

collaborator

University Clinical Hospital Military Medical Academy, Central Veterans Hospital in Łódź

UNKNOWN

collaborator

Medical University of Gdansk

OTHER

collaborator

Autonomous Public Specialist Western John Paul II Hospital in Grodzisk Mazowiecki

UNKNOWN

collaborator

Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz

OTHER

collaborator

Poznan University of Medical Sciences

OTHER

collaborator

John Paul II Hospital, Krakow

OTHER

collaborator

Ludwik Rydygier Regional Polyclinical Hospital in Toruń

UNKNOWN

collaborator

University Teaching Hospital in Białystok

UNKNOWN

collaborator

Medical University of Silesia in Katowice

UNKNOWN

lead

Medical University of Warsaw

OTHER